VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs). VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and...
OPKO Health, Inc. (NASDAQ: OPK) today announced that the last patient has completed the final visit in the Company’s pivotal Phase 3 study evaluating the safety and efficacy of the once weekly somatrogon (hGH-CTP) for treatment of growth hormone deficiency in...
PHILADELPHIA, August 27, 2019 – Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia developing novel compounds to treat neurodegenerative diseases, announces the publication of its Phase 2a RASMET study. The article...
– SurModics, Inc.(NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal clinical trial for the SurVeil™ drug-coated balloon...
– QIDP and FDA-Fast-Track-Designated first of a new class of antibiotics – First evidence of human safety in multiple ascending doses and favorable PK profile – Fecal concentrations exceeded those known to inhibit C. difficile several hundred-fold...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of the Phase 3 BouNDless study investigating the efficacy, safety and tolerability of ND0612, a potential non-surgical, subcutaneous continuous treatment, compared to oral immediate-release...
Email
Text